Pharmaceutical Cannabis - Denmark

Denmark

In Denmark, revenue in the Pharmaceutical Cannabis market is forecasted to reach US$10.55m by 2024.
The revenue is anticipated to demonstrate an annual growth rate (CAGR 2024-2029) of 4.30%, leading to a market volume of US$13.02m by 2029.
When compared globally, the United States is expected to generate the most revenue, amounting to US$913.10m in 2024.
In terms of per person revenues in 2024, in Denmark records US$8.74k.
Denmark's pharmaceutical cannabis market is growing rapidly, with increased research and development focusing on medical applications and quality standards.

Key regions: United States, Spain, Europe, Thailand, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

Denmark has been experiencing a notable growth in the Pharmaceutical Cannabis market, reflecting a global trend towards the acceptance and legalization of medical cannabis.

Customer preferences: Customers in Denmark are increasingly seeking alternative and natural remedies for various health conditions, which has led to a growing interest in pharmaceutical cannabis products. The shift towards more holistic and organic treatments has driven demand for medical cannabis in the country.

Trends in the market: One of the key trends in the Pharmaceutical Cannabis market in Denmark is the expanding range of available products and consumption methods. With advancements in research and technology, pharmaceutical cannabis companies are introducing innovative formulations and delivery systems to cater to diverse patient needs. Additionally, there is a rising focus on personalized medicine, with companies offering tailored treatment options based on individual requirements.

Local special circumstances: Denmark's progressive regulatory environment and supportive government policies have played a significant role in shaping the Pharmaceutical Cannabis market. The country has implemented a well-defined framework for the cultivation, production, and distribution of medical cannabis, providing a secure and transparent ecosystem for industry players. Moreover, Denmark's strong healthcare infrastructure and high-quality standards further contribute to the growth of the pharmaceutical cannabis sector.

Underlying macroeconomic factors: The growth of the Pharmaceutical Cannabis market in Denmark is also influenced by broader macroeconomic factors such as increasing healthcare expenditures and changing demographics. As the population ages and the prevalence of chronic diseases rises, there is a growing need for effective treatment options like medical cannabis. Furthermore, the economic stability and high disposable income levels in Denmark support the affordability and accessibility of pharmaceutical cannabis products for patients.

Methodology

Data coverage:

Data encompasses B2B and B2C enterprises. Figures are based on companies' revenues, funding values and global consumer survey data. Revenues include retail, sales and taxes.

Modeling approach / Market size:

Market sizes are determined by a Top-Down approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports, third-party data. Next, we use relevant key market indicators and data from country-specific associations such as tobacco spending per capita, medical product spending per capita, consumer spending and consumer spending for recreation purposes, population. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.